SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (3809)3/11/2004 8:31:47 PM
From: scaram(o)ucheRead Replies (1) | Respond to of 4974
 
it implies, a huge maybe, that you'll see less sepsis than otherwise.... that those started on it may see some prophylaxis? the mechanism for gemifloxacin, and how it might differ from that of fluoroquinolones in general, seems to be of interest. such studies could be a source of marketing muscle.

but.... LPS in an in vitro model? this really is as weak as a signal can get.